JAK1 Inhibitor Salts and Crystalline Forms for Lower-Dose Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory conditions, autoimmune diseases, and other related disorders are inadequate, leading to patient intolerance, side effects, and low compliance due to long-term treatment requirements, necessitating the development of new therapeutic agents with improved dosage regimens and reduced side effects.
Innovation Solution
Development of novel salts and crystalline forms of a JAK1 inhibitor, specifically Compound 1, which are more soluble and bioavailable, allowing for lower dosages and potentially reducing toxicity and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for long-term treatment, then therapeutic effect is maintained, but patient compliance deteriorates due to intolerance and side effects
Solution Approach 1:
The patent modifies the chemical parameters of the JAK1 inhibitor by creating novel salts and crystalline forms with different solubility and bioavailability characteristics. This allows achieving the same therapeutic effect at lower dosages, thereby improving patient compliance while maintaining therapeutic reliability.
Solution Approach 2:
The patent creates alternative forms (salts and crystalline forms) of the same active compound, effectively copying the therapeutic function while improving the pharmacokinetic properties. This allows the drug to achieve better bioavailability and reduce side effects at lower doses.
2Reliability
If high dosage is administered, then therapeutic effect is enhanced, but side effects increase
Solution Approach 1:
The patent changes the physical and chemical parameters of the compound by developing novel salts and crystalline forms with improved solubility and bioavailability. This enables achieving therapeutic effects at lower dosages, thereby reducing side effects while maintaining therapeutic reliability.
Solution Approach 2:
The patent replaces the need for high-dose mechanical administration with optimized pharmacokinetic properties through salt and crystalline form modification. This substitution allows lower dosages to achieve the same therapeutic effect, reducing harmful side effects.
3Reliability
If repeated intake is required for chronic conditions, then disease control is maintained, but patient burden increases
Solution Approach 1:
The patent modifies the pharmacokinetic parameters of the JAK1 inhibitor through novel salt and crystalline form development, achieving improved bioavailability and potentially extended duration of action. This reduces the frequency of dosing while maintaining disease control, thereby reducing patient burden.
Data Source
AI summary
The present invention discloses salts of a Compound 1:useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.